{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T10:40:07Z","timestamp":1762252807437,"version":"3.41.0"},"reference-count":173,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780128151419"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.irn.2018.08.007","type":"book-chapter","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T18:25:04Z","timestamp":1535567104000},"page":"289-333","source":"Crossref","is-referenced-by-count":10,"title":["Molecular Imaging in Huntington's Disease"],"prefix":"10.1016","author":[{"given":"Heather","family":"Wilson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Politis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1212\/WNL.0000000000000037","article-title":"PET imaging shows loss of striatal PDE10A in patients with Huntington disease","volume":"82","author":"Ahmad","year":"2014","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00004714-199808000-00012","article-title":"Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain","volume":"18","author":"Andree","year":"1998","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0020","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1093\/brain\/122.12.2353","article-title":"Huntington's disease progression PET and clinical observations","volume":"122","author":"Andrews","year":"1999","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0025","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ana.410430216","article-title":"[11C]raclopride-PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length","volume":"43","author":"Antonini","year":"1998","journal-title":"Annals of Neurology"},{"issue":"Pt. 6","key":"10.1016\/bs.irn.2018.08.007_bb0030","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/brain\/119.6.2085","article-title":"Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease","volume":"119","author":"Antonini","year":"1996","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/sj.bjp.0704053","article-title":"Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices","volume":"133","author":"Arias-Montano","year":"2001","journal-title":"British Journal of Pharmacology"},{"issue":"5911","key":"10.1016\/bs.irn.2018.08.007_bb0040","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/302832a0","article-title":"Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor","volume":"302","author":"Arrang","year":"1983","journal-title":"Nature"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0045","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2967\/jnumed.109.071753","article-title":"Evaluation of 11C-GSK189254 as a novel radioligand for the H3 receptor in humans using PET","volume":"51","author":"Ashworth","year":"2010","journal-title":"Journal of Nuclear Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/1467-9450.00238","article-title":"Dopamine and cognitive functioning: Brain imaging findings in Huntington's disease and normal aging","volume":"42","author":"Backman","year":"2001","journal-title":"Scandinavian Journal of Psychology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0055","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1093\/brain\/120.12.2207","article-title":"Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes","volume":"120","author":"Backman","year":"1997","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0060","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/glia.10144","article-title":"Visualising microglial activation in vivo","volume":"40","author":"Banati","year":"2002","journal-title":"Glia"},{"issue":"Pt. 9","key":"10.1016\/bs.irn.2018.08.007_bb0065","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/brain\/120.9.1553","article-title":"Central motor processing in Huntington's disease. A PET study","volume":"120","author":"Bartenstein","year":"1997","journal-title":"Brain"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0070","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1053-8119(03)00241-6","article-title":"In vivo imaging of adenosine A1 receptors in the human brain with [18F]CPFPX and positron emission tomography","volume":"19","author":"Bauer","year":"2003","journal-title":"NeuroImage"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0075","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/ana.410230603","article-title":"Positron emission tomographic scan investigations of Huntington's disease: Cerebral metabolic correlates of cognitive function","volume":"23","author":"Berent","year":"1988","journal-title":"Annals of Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.007_bb0080","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1084\/jem.20080178","article-title":"A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease","volume":"205","author":"Bjorkqvist","year":"2008","journal-title":"The Journal of Experimental Medicine"},{"issue":"3\u20134","key":"10.1016\/bs.irn.2018.08.007_bb0085","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/0028-3908(94)90059-0","article-title":"Molecular biology of 5-HT receptors","volume":"33","author":"Boess","year":"1994","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0090","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1212\/WNL.54.9.1753","article-title":"Decreased striatal monoaminergic terminals in Huntington disease","volume":"54","author":"Bohnen","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0095","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2015.08.013","article-title":"Histamine and the striatum","volume":"106","author":"Bolam","year":"2016","journal-title":"Neuropharmacology"},{"issue":"52","key":"10.1016\/bs.irn.2018.08.007_bb0100","doi-asserted-by":"crossref","first-page":"22480","DOI":"10.1073\/pnas.0911503106","article-title":"Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms","volume":"106","author":"Bradford","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0006-8993(95)00104-X","article-title":"The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain","volume":"676","author":"Burnet","year":"1995","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0110","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.nurt.2007.04.006","article-title":"Positron emission tomography imaging of neuroinflammation","volume":"4","author":"Cagnin","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0115","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1073\/pnas.94.6.2665","article-title":"Decreased probability of neurotransmitter release underlies striatal long-term depression and postnatal development of corticostriatal synapses","volume":"94","author":"Choi","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0120","first-page":"215","article-title":"Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease","volume":"47","author":"Ciarmiello","year":"2006","journal-title":"Journal of Nuclear Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0125","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s00259-012-2114-z","article-title":"F-18-FDG PET uptake in the pre-Huntington disease caudate affects the time-to-onset independently of CAG expansion size","volume":"39","author":"Ciarmiello","year":"2012","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.007_bb0130","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1369\/jhc.6A6930.2006","article-title":"Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species","volume":"54","author":"Coskran","year":"2006","journal-title":"Journal of Histochemistry and Cytochemistry"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0135","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nn.3668","article-title":"Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors","volume":"17","author":"Crotti","year":"2014","journal-title":"Nature Neuroscience"},{"issue":"15","key":"10.1016\/bs.irn.2018.08.007_bb0140","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1002\/mds.22809","article-title":"A pilot study using nabilone for symptomatic treatment in Huntington's disease","volume":"24","author":"Curtis","year":"2009","journal-title":"Movement Disorders"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0166-2236(98)01304-6","article-title":"Cellular mechanisms of cerebellar LTD","volume":"21","author":"Daniel","year":"1998","journal-title":"Trends in Neurosciences"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0006-8993(86)91469-1","article-title":"Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains","volume":"372","author":"Dawbarn","year":"1986","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0155","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.neuroscience.2007.11.044","article-title":"Cortical expression of brain derived neurotrophic factor and type-1 cannabinoid receptor after striatal excitotoxic lesions","volume":"152","author":"De March","year":"2008","journal-title":"Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/0306-4522(94)90179-1","article-title":"Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system","volume":"59","author":"De Vos","year":"1994","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.007_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0006-8993(91)91675-Q","article-title":"Autoradiographic distribution of alpha 2 adrenoceptors, NAIBS, and 5-HT1A receptors in human brain using [3H]idazoxan and [3H]rauwolscine","volume":"566","author":"De Vos","year":"1991","journal-title":"Brain Research"},{"issue":"1 Pt. 2","key":"10.1016\/bs.irn.2018.08.007_bb0170","article-title":"Coupling of cerebral blood flow to neuronal activation: Role of adenosine and nitric oxide","volume":"267","author":"Dirnagl","year":"1994","journal-title":"The American Journal of Physiology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0175","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0028-3908(00)00101-5","article-title":"Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway","volume":"40","author":"Doreulee","year":"2001","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0180","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.neuroscience.2009.06.014","article-title":"Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease","volume":"163","author":"Dowie","year":"2009","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0185","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.20075","article-title":"Paroxetine retards disease onset and progression in Huntingtin mutant mice","volume":"55","author":"Duan","year":"2004","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0190","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.nbd.2008.01.015","article-title":"Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease","volume":"30","author":"Duan","year":"2008","journal-title":"Neurobiology of Disease"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0165-6147(98)01244-9","article-title":"'Seeing through a glass darkly': casting light on imidazoline 'I' sites","volume":"19","author":"Eglen","year":"1998","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0200","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1172\/JCI45646","article-title":"Brain networks in Huntington disease","volume":"121","author":"Eidelberg","year":"2011","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0205","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bph.12221","article-title":"Histamine H(3) receptors, the complex interaction with dopamine and its implications for addiction","volume":"170","author":"Ellenbroek","year":"2013","journal-title":"British Journal of Pharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tins.2014.02.007","article-title":"The other side of the histamine H3 receptor","volume":"37","author":"Ellenbroek","year":"2014","journal-title":"Trends in Neurosciences"},{"issue":"43","key":"10.1016\/bs.irn.2018.08.007_bb0215","doi-asserted-by":"crossref","first-page":"15340","DOI":"10.1523\/JNEUROSCI.3144-11.2011","article-title":"Differential modulation of excitatory and inhibitory striatal synaptic transmission by histamine","volume":"31","author":"Ellender","year":"2011","journal-title":"The Journal of Neuroscience"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.007_bb0220","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2967\/jnumed.112.115576","article-title":"In vivo kinetic and steady-state quantification of 18F-CPFPX binding to rat cerebral A1 adenosine receptors: Validation by displacement and autoradiographic experiments","volume":"54","author":"Elmenhorst","year":"2013","journal-title":"Journal of Nuclear Medicine"},{"issue":"10","key":"10.1016\/bs.irn.2018.08.007_bb0225","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/hbm.21134","article-title":"Extrastriatal dopamine D-2 receptor binding in Huntington's disease","volume":"32","author":"Esmaeilzadeh","year":"2011","journal-title":"Human Brain Mapping"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0230","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0304-3940(86)90291-0","article-title":"Adenosine A1-receptors in human brain: Characterization and autoradiographic visualization","volume":"65","author":"Fastbom","year":"1986","journal-title":"Neuroscience Letters"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.007_bb0235","first-page":"1591","article-title":"Metabolic network abnormalities in early Huntington's disease: An F-18 FDG PET study","volume":"42","author":"Feigin","year":"2001","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/bs.irn.2018.08.007_bb0240","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1093\/brain\/awm217","article-title":"Thalamic metabolism and symptom onset in preclinical Huntington's disease","volume":"130","author":"Feigin","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0245","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00004728-198503000-00001","article-title":"Imaging opiate receptors in the human brain by positron tomography","volume":"9","author":"Frost","year":"1985","journal-title":"Journal of Computer Assisted Tomography"},{"issue":"26","key":"10.1016\/bs.irn.2018.08.007_bb0250","doi-asserted-by":"crossref","first-page":"18438","DOI":"10.1074\/jbc.274.26.18438","article-title":"Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)","volume":"274","author":"Fujishige","year":"1999","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0255","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0306-4522(97)00100-0","article-title":"Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata","volume":"80","author":"Garcia","year":"1997","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0260","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1152\/jn.2001.85.1.468","article-title":"CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum","volume":"85","author":"Gerdeman","year":"2001","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/brain\/120.3.503","article-title":"PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease","volume":"120","author":"Ginovart","year":"1997","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2018.08.007_bb0270","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-3-7091-0932-8_18","article-title":"Integrating neurotransmission in striatal medium spiny neurons","volume":"970","author":"Girault","year":"2012","journal-title":"Synaptic Plasticity: Dynamics, Development and Disease"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0275","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1460-9568.1997.tb01390.x","article-title":"Modulation of neurotransmission by cannabinoids in the basal ganglia","volume":"9","author":"Glass","year":"1997","journal-title":"European Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0280","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1460-9568.1999.00453.x","article-title":"Distribution of histamine H3-receptor binding in the normal human basal ganglia: Comparison with Huntington's and Parkinson's disease cases","volume":"11","author":"Goodchild","year":"1999","journal-title":"The European Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0896-6273(00)80798-9","article-title":"Beyond the dopamine receptor: The DARPP-32\/protein phosphatase-1 cascade","volume":"23","author":"Greengard","year":"1999","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0290","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1189\/jlb.0303114","article-title":"Microglia, macrophages, perivascular macrophages, and pericytes: A review of function and identification","volume":"75","author":"Guillemin","year":"2004","journal-title":"Journal of Leukocyte Biology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0295","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.neuroscience.2003.11.009","article-title":"Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms","volume":"123","author":"Hebb","year":"2004","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0300","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/00005072-199501000-00013","article-title":"Early loss of neostriatal striosome neurons in Huntington's disease","volume":"54","author":"Hedreen","year":"1995","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0305","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s00415-014-7350-7","article-title":"Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington's disease","volume":"261","author":"Herben-Dekker","year":"2014","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0310","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ana.410340114","article-title":"Positron emission tomography measures of benzodiazepine receptors in Huntington's disease","volume":"34","author":"Holthoff","year":"1993","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0315","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1111\/j.1460-9568.2004.03796.x","article-title":"Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A","volume":"20","author":"Hu","year":"2004","journal-title":"European Journal of Neuroscience"},{"issue":"Pt. 3","key":"10.1016\/bs.irn.2018.08.007_bb0320","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1469-7793.2001.0731e.x","article-title":"Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons","volume":"532","author":"Huang","year":"2001","journal-title":"The Journal of Physiology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0325","first-page":"208","article-title":"PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907","volume":"39","author":"Ito","year":"1998","journal-title":"Journal of Nuclear Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0330","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2967\/jnumed.112.108258","article-title":"Imaging imidazoline-I2 binding sites in porcine brain using 11C-BU99008","volume":"54","author":"Kealey","year":"2013","journal-title":"Journal of Nuclear Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0335","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nn.3318","article-title":"Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways","volume":"16","author":"Kierdorf","year":"2013","journal-title":"Nature Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0340","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.nucmedbio.2009.08.013","article-title":"In vivo [11C]dihydrotetrabenazine binding in rat striatum: Sensitivity to dopamine concentrations","volume":"37","author":"Kilbourn","year":"2010","journal-title":"Nuclear Medicine and Biology"},{"issue":"7128","key":"10.1016\/bs.irn.2018.08.007_bb0345","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nature05506","article-title":"Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models","volume":"445","author":"Kreitzer","year":"2007","journal-title":"Nature"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0350","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/ana.410120504","article-title":"Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan","volume":"12","author":"Kuhl","year":"1982","journal-title":"Annals of Neurology"},{"issue":"15","key":"10.1016\/bs.irn.2018.08.007_bb0355","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/hmg\/ddm133","article-title":"Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage","volume":"16","author":"Kuhn","year":"2007","journal-title":"Human Molecular Genetics"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0360","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1531-8249(200005)47:5<644::AID-ANA13>3.0.CO;2-C","article-title":"Benzodiazepine receptor binding in Huntington's disease: [11C]Flumazenil uptake measured using positron emission tomography","volume":"47","author":"Kunig","year":"2000","journal-title":"Annals of Neurology"},{"issue":"Pt. 5","key":"10.1016\/bs.irn.2018.08.007_bb0365","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/brain\/113.5.1405","article-title":"Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease","volume":"113","author":"Kuwert","year":"1990","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0370","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0375","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clinical Genetics"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0380","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches","volume":"153B","author":"Langbehn","year":"2010","journal-title":"American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0385","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(01)03403-5","article-title":"Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease","volume":"929","author":"Lastres-Becker","year":"2002","journal-title":"Brain Research"},{"issue":"Pt. 7","key":"10.1016\/bs.irn.2018.08.007_bb0390","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/brain\/121.7.1343","article-title":"The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease","volume":"121","author":"Lawrence","year":"1998","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0395","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1631","article-title":"The histamine H3 receptor: From gene cloning to H3 receptor drugs","volume":"4","author":"Leurs","year":"2005","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0400","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1006\/nbdi.2001.0430","article-title":"Impaired glutamate uptake in the R6 Huntington's disease transgenic mice","volume":"8","author":"Lievens","year":"2001","journal-title":"Neurobiology of Disease"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0405","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1007\/s00259-016-3445-y","article-title":"Striatal hypometabolism in premanifest and manifest Huntington's disease patients","volume":"43","author":"Lopez-Mora","year":"2016","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.007_bb0410","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(92)90832-R","article-title":"Localization of cannabinoid receptor in the human developing and adult basal ganglia\u2014Higher levels in the striatonigral neurons","volume":"148","author":"Mailleux","year":"1992","journal-title":"Neuroscience Letters"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0415","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.neulet.2009.10.011","article-title":"BDNF regulates neuronal sensitivity to endocannabinoids","volume":"467","author":"Maison","year":"2009","journal-title":"Neuroscience Letters"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0420","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/archneur.58.3.365","article-title":"Glutamate transporters in neurologic disease","volume":"58","author":"Maragakis","year":"2001","journal-title":"Archives of Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0425","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/ncpneuro0355","article-title":"Mechanisms of disease: Astrocytes in neurodegenerative disease","volume":"2","author":"Maragakis","year":"2006","journal-title":"Nature Clinical Practice. Neurology"},{"issue":"5642","key":"10.1016\/bs.irn.2018.08.007_bb0430","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0435","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.arr.2004.08.001","article-title":"A neural signaling triumvirate that influences ageing and age-related disease: Insulin\/IGF-1, BDNF and serotonin","volume":"3","author":"Mattson","year":"2004","journal-title":"Ageing Research Reviews"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0440","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00259-014-2724-8","article-title":"Cross sectional PET study of cerebral adenosine A(1) receptors in premanifest and manifest Huntington's disease","volume":"41","author":"Matusch","year":"2014","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1471-4914(02)02276-1","article-title":"Cannabinoids and brain injury: Therapeutic implications","volume":"8","author":"Mechoulam","year":"2002","journal-title":"Trends in Molecular Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0450","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00001756-200001170-00032","article-title":"Histamine H3-receptor activation inhibits dopamine synthesis in rat striatum","volume":"11","author":"Molina-Hernandez","year":"2000","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0455","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1385\/MN:27:2:163","article-title":"Microglial functions and proteases","volume":"27","author":"Nakanishi","year":"2003","journal-title":"Molecular Neurobiology"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.007_bb0460","doi-asserted-by":"crossref","first-page":"7539","DOI":"10.1523\/JNEUROSCI.15-11-07539.1995","article-title":"Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments","volume":"15","author":"Nibuya","year":"1995","journal-title":"The Journal of Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0465","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1523\/JNEUROSCI.16-07-02365.1996","article-title":"Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus","volume":"16","author":"Nibuya","year":"1996","journal-title":"The Journal of Neuroscience"},{"issue":"Pt. 10","key":"10.1016\/bs.irn.2018.08.007_bb0470","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1093\/brain\/awv214","article-title":"Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease","volume":"138","author":"Niccolini","year":"2015","journal-title":"Brain"},{"key":"10.1016\/bs.irn.2018.08.007_bb0475","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jnnp-2017-316633","article-title":"Striatal molecular alterations in HD gene carriers: A systematic review and meta-analysis of PET studies","volume":"89","author":"Niccolini","year":"2018","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0480","doi-asserted-by":"crossref","first-page":"301","DOI":"10.4329\/wjr.v6.i6.301","article-title":"Neuroimaging in Huntington's disease","volume":"6","author":"Niccolini","year":"2014","journal-title":"World Journal of Radiology"},{"issue":"42","key":"10.1016\/bs.irn.2018.08.007_bb0485","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1523\/JNEUROSCI.2518-08.2008","article-title":"Distinct roles of PDE4 and PDE10A in the regulation of cAMP\/PKA signaling in the striatum","volume":"28","author":"Nishi","year":"2008","journal-title":"Journal of Neuroscience"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0490","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1254\/jphs.10R01FM","article-title":"Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission","volume":"114","author":"Nishi","year":"2010","journal-title":"Journal of Pharmacological Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0495","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1476-5381.1994.tb14842.x","article-title":"The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain","volume":"111","author":"Olmos","year":"1994","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.410260103","article-title":"A quantitative investigation of the substantia nigra in Huntington's disease","volume":"26","author":"Oyanagi","year":"1989","journal-title":"Annals of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0505","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00259-016-3324-6","article-title":"Current status of PET imaging in Huntington's disease","volume":"43","author":"Pagano","year":"2016","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0510","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/hmg\/ddn385","article-title":"Altered serotonin receptor expression is associated with depression-related behavior in the R6\/1 transgenic mouse model of Huntington's disease","volume":"18","author":"Pang","year":"2009","journal-title":"Human Molecular Genetics"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0515","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-6147(96)81564-1","article-title":"The elusive family of imidazoline binding sites","volume":"17","author":"Parini","year":"1996","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0520","doi-asserted-by":"crossref","first-page":"838","DOI":"10.2967\/jnumed.113.131854","article-title":"Evaluation of 11C-BU99008, a PET ligand for the imidazoline2 binding sites in rhesus brain","volume":"55","author":"Parker","year":"2014","journal-title":"Journal of Nuclear Medicine"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.007_bb0525","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0169-328X(96)00026-5","article-title":"Comparative anatomical distribution of serotonin 1A, 1D alpha and 2A receptor mRNAs in human brain postmortem","volume":"39","author":"Pasqualetti","year":"1996","journal-title":"Brain Research. Molecular Brain Research"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0530","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1001\/archneur.63.6.883","article-title":"Preparing for preventive clinical trials: The predict-HD study","volume":"63","author":"Paulsen","year":"2006","journal-title":"Archives of Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.007_bb0535","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/jnnp.2007.128728","article-title":"Detection of Huntington's disease decades before diagnosis: The predict-HD study","volume":"79","author":"Paulsen","year":"2008","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2018.08.007_bb0540","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/brain\/awg119","article-title":"Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: A PET study","volume":"126","author":"Pavese","year":"2003","journal-title":"Brain"},{"issue":"11","key":"10.1016\/bs.irn.2018.08.007_bb0545","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1212\/01.wnl.0000222734.56412.17","article-title":"Microglial activation correlates with severity in Huntington disease: A clinical and PET study","volume":"66","author":"Pavese","year":"2006","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0550","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nbd.2009.10.015","article-title":"Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers","volume":"37","author":"Pavese","year":"2010","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0555","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.expneurol.2007.10.015","article-title":"The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6\/2 Huntington's disease mouse model","volume":"210","author":"Peng","year":"2008","journal-title":"Experimental Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0560","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/ana.410410521","article-title":"CAG repeat number governs the development rate of pathology in Huntington's disease","volume":"41","author":"Penney","year":"1997","journal-title":"Annals of Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0565","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/WNL.32.12.1391","article-title":"Quantitative autoradiography of neurotransmitter receptors in Huntington disease","volume":"32","author":"Penney","year":"1982","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0570","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJM197302152880703","article-title":"Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain","volume":"288","author":"Perry","year":"1973","journal-title":"The New England Journal of Medicine"},{"issue":"16","key":"10.1016\/bs.irn.2018.08.007_bb0575","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1523\/JNEUROSCI.22-16-07272.2002","article-title":"Ciproxifan, a histamine H3-receptor antagonist\/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat","volume":"22","author":"Pillot","year":"2002","journal-title":"The Journal of Neuroscience"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0580","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2967\/jnumed.113.131409","article-title":"Phosphodiesterase 10A PET radioligand development program: From pig to human","volume":"55","author":"Plisson","year":"2014","journal-title":"Journal of Nuclear Medicine"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0585","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nrneurol.2014.205","article-title":"Neuroimaging in Parkinson disease: From research setting to clinical practice","volume":"10","author":"Politis","year":"2014","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0590","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nbd.2015.08.011","article-title":"Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington's disease gene carriers","volume":"83","author":"Politis","year":"2015","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/bs.irn.2018.08.007_bb0595","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2014.07.037","article-title":"Serotonin in Parkinson's disease","volume":"277","author":"Politis","year":"2015","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0600","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hbm.21008","article-title":"Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study","volume":"32","author":"Politis","year":"2011","journal-title":"Human Brain Mapping"},{"issue":"Pt. 11","key":"10.1016\/bs.irn.2018.08.007_bb0605","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1093\/brain\/awn244","article-title":"Hypothalamic involvement in Huntington's disease: An in vivo PET study","volume":"131","author":"Politis","year":"2008","journal-title":"Brain"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0610","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0306-4522(93)90191-H","article-title":"A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas","volume":"52","author":"Pollard","year":"1993","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0615","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s002109900097","article-title":"Histaminergic neurons modulate acetylcholine release in the ventral striatum: Role of H3 histamine receptors","volume":"360","author":"Prast","year":"1999","journal-title":"Naunyn-Schmiedeberg's Archives of Pharmacology"},{"issue":"15","key":"10.1016\/bs.irn.2018.08.007_bb0620","doi-asserted-by":"crossref","first-page":"5733","DOI":"10.1073\/pnas.85.15.5733","article-title":"Differential loss of striatal projection neurons in Huntington disease","volume":"85","author":"Reiner","year":"1988","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0625","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022133","article-title":"Sexually dimorphic serotonergic dysfunction in a mouse model of Huntington's disease and depression","volume":"6","author":"Renoir","year":"2011","journal-title":"PLoS One"},{"issue":"1\u20133","key":"10.1016\/bs.irn.2018.08.007_bb0630","article-title":"Imidazoline binding sites in Huntington's and Parkinson's disease putamen","volume":"301","author":"Reynolds","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0635","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuroimage.2014.04.020","article-title":"Test\u2013retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [(1)(1)C]MePPEP","volume":"97","author":"Riano Barros","year":"2014","journal-title":"NeuroImage"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0640","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: Natural history, biomarkers and prospects for therapeutics","volume":"10","author":"Ross","year":"2014","journal-title":"Nature Reviews Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0645","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1001\/jamaneurol.2014.1954","article-title":"The phosphodiesterase 10 positron emission tomography tracer, [18F]MNI-659, as a novel biomarker for early Huntington disease","volume":"71","author":"Russell","year":"2014","journal-title":"JAMA Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.007_bb0650","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1212\/WNL.0000000000002391","article-title":"Change in PDE10 across early Huntington disease assessed by [18F]MNI-659 and PET imaging","volume":"86","author":"Russell","year":"2016","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0655","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/jcbfm.1991.52","article-title":"Quantification of human opiate receptor concentration and affinity using high and low specific activity [11C]diprenorphine and positron emission tomography","volume":"11","author":"Sadzot","year":"1991","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0660","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1471-4159.1993.tb03599.x","article-title":"Opposite age-dependent changes of alpha 2A-adrenoceptors and nonadrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) in the human brain: Strong correlation of I2 with monoamine oxidase-B sites","volume":"61","author":"Sastre","year":"1993","journal-title":"Journal of Neurochemistry"},{"issue":"8","key":"10.1016\/bs.irn.2018.08.007_bb0665","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.1073\/pnas.96.8.4604","article-title":"Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology","volume":"96","author":"Scherzinger","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/bs.irn.2018.08.007_bb0670","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/BF02191583","article-title":"Dopamine D1 receptor number\u2014A sensitive PET marker for early brain degeneration in Huntington's disease","volume":"243","author":"Sedvall","year":"1994","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0675","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","article-title":"Immunohistochemical localization of PDE10A in the rat brain","volume":"985","author":"Seeger","year":"2003","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0680","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0006-8993(86)90946-7","article-title":"Opioid peptides in Huntington's disease: Alterations in prodynorphin and proenkephalin system","volume":"378","author":"Seizinger","year":"1986","journal-title":"Brain Research"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0685","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/mol.54.3.459","article-title":"Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity","volume":"54","author":"Shen","year":"1998","journal-title":"Molecular Pharmacology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0690","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1083\/jcb.200508072","article-title":"Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity","volume":"171","author":"Shin","year":"2005","journal-title":"The Journal of Cell Biology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0695","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3988\/jcn.2013.9.1.21","article-title":"Decreased metabolism in the cerebral cortex in early-stage Huntington's disease: A possible biomarker of disease progression?","volume":"9","author":"Shin","year":"2013","journal-title":"Journal of Clinical Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2018.08.007_bb0700","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","article-title":"Distinct neuroinflammatory profile in post-mortem human Huntington's disease","volume":"20","author":"Silvestroni","year":"2009","journal-title":"Neuroreport"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0705","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.neuropharm.2006.01.012","article-title":"Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: Evidence for altered striatal function","volume":"51","author":"Siuciak","year":"2006","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/jcbfm.1981.4","article-title":"Localization of functional activity in the central nervous system by measurement of glucose utilization with radioactive deoxyglucose","volume":"1","author":"Sokoloff","year":"1981","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0715","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1023\/A:1022534709672","article-title":"Energetics of functional activation in neural tissues","volume":"24","author":"Sokoloff","year":"1999","journal-title":"Neurochemical Research"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0720","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0022-3565(25)38366-7","article-title":"Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: Behavioral, electrophysiological and neurochemical studies","volume":"266","author":"Sorensen","year":"1993","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0725","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(93)90073-Q","article-title":"Reduced levels of 5-HT3 receptor recognition sites in the putamen of patients with Huntington's disease","volume":"242","author":"Steward","year":"1993","journal-title":"European Journal of Pharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0730","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/syn.1089","article-title":"Vesicular neurotransmitter transporters in Huntington's disease: Initial observations and comparison with traditional synaptic markers","volume":"41","author":"Suzuki","year":"2001","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/bs.irn.2018.08.007_bb0735","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/(SICI)1098-2396(199712)27:4<322::AID-SYN6>3.0.CO;2-E","article-title":"Distribution of adenosine receptors in the postmortem human brain: An extended autoradiographic study","volume":"27","author":"Svenningsson","year":"1997","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0740","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0306-4522(97)00597-6","article-title":"Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum","volume":"85","author":"Szabo","year":"1998","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0745","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S1474-4422(09)70170-X","article-title":"Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data","volume":"8","author":"Tabrizi","year":"2009","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0750","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1474-4422(11)70263-0","article-title":"Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: Analysis of 24 month observational data","volume":"11","author":"Tabrizi","year":"2012","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0755","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1474-4422(10)70276-3","article-title":"Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis","volume":"10","author":"Tabrizi","year":"2011","journal-title":"Lancet Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2018.08.007_bb0760","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S1474-4422(13)70088-7","article-title":"Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data","volume":"12","author":"Tabrizi","year":"2013","journal-title":"Lancet Neurology"},{"issue":"Pt. 7","key":"10.1016\/bs.irn.2018.08.007_bb0765","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awm044","article-title":"Microglial activation in presymptomatic Huntington's disease gene carriers","volume":"130","author":"Tai","year":"2007","journal-title":"Brain"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0770","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1172\/JCI69411","article-title":"Metabolic network as a progression biomarker of premanifest Huntington's disease","volume":"123","author":"Tang","year":"2013","journal-title":"The Journal of Clinical Investigation"},{"issue":"Pt. 3","key":"10.1016\/bs.irn.2018.08.007_bb0775","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/brain\/118.3.689","article-title":"Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study","volume":"118","author":"Turjanski","year":"1995","journal-title":"Brain"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0780","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/syn.21541","article-title":"Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2-(4,5-dihydro-1H-imidazol-2-yl)-1-methyl-1H-indole), for the imidazoline(2) binding site","volume":"66","author":"Tyacke","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/bs.irn.2018.08.007_bb0785","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.118.208009","article-title":"Evaluation of (11)C-BU99008, a positron emission tomography ligand for the Imidazoline2 binding site in human brain","author":"Tyacke","year":"2018","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/bs.irn.2018.08.007_bb9171","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2967\/jnumed.110.077156","article-title":"Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo","volume":"51","author":"Van Laere","year":"2010","journal-title":"The Journal of Nuclear Medicine"},{"issue":"1","key":"10.1016\/bs.irn.2018.08.007_bb0790","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2967\/jnumed.113.122515","article-title":"(11)C-MK-8278 PET as a tool for pharmacodynamic brain occupancy of histamine 3 receptor inverse agonists","volume":"55","author":"Van Laere","year":"2014","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0795","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1331.2008.02390.x","article-title":"Changes in striatal dopamine D2 receptor binding in pre-clinical Huntington's disease","volume":"16","author":"van Oostrom","year":"2009","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0800","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1212\/01.wnl.0000176071.08694.cc","article-title":"Striatal dopamine D2 receptors, metabolism, and volume in preclinical Huntington disease","volume":"65","author":"van Oostrom","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0805","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/S0072-9752(07)01256-0","article-title":"Neuropathology of Huntington's disease","volume":"89","author":"Vonsattel","year":"2008","journal-title":"Handbook of Clinical Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0810","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","article-title":"Neuropathological classification of Huntington's disease","volume":"44","author":"Vonsattel","year":"1985","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0815","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0306-4522(89)90082-1","article-title":"Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: A quantitative in vitro autoradiography study","volume":"32","author":"Waeber","year":"1989","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0820","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1212\/WNL.34.9.1237","article-title":"Benzodiazepine and GABA receptors in early Huntington's disease","volume":"34","author":"Walker","year":"1984","journal-title":"Neurology"},{"issue":"Pt. 9","key":"10.1016\/bs.irn.2018.08.007_bb0825","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/brain\/120.9.1569","article-title":"Cortical control of movement in Huntington's disease. A PET activation study","volume":"120","author":"Weeks","year":"1997","journal-title":"Brain"},{"issue":"9","key":"10.1016\/bs.irn.2018.08.007_bb0830","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1097\/00004647-199709000-00003","article-title":"11C-diprenorphine binding in Huntington's disease: A comparison of region of interest analysis with statistical parametric mapping","volume":"17","author":"Weeks","year":"1997","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/bs.irn.2018.08.007_bb9172","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/ana.410400110","article-title":"Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease","volume":"40","author":"Weeks","year":"1996","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0835","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3389\/fneur.2017.00011","article-title":"Molecular imaging markers to track Huntington's disease pathology","volume":"8","author":"Wilson","year":"2017","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/bs.irn.2018.08.007_bb0840","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jns.2016.07.033","article-title":"Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers","volume":"368","author":"Wilson","year":"2016","journal-title":"Journal of the Neurological Sciences"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2018.08.007_bb0845","first-page":"249","article-title":"Characterization of [3H]GR 113808 binding to 5-HT4 receptors in brain tissues from patients with neurodegenerative disorders","volume":"73","author":"Wong","year":"1996","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2018.08.007_bb0850","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neuroscience.2005.12.042","article-title":"Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase","volume":"139","author":"Xie","year":"2006","journal-title":"Neuroscience"},{"issue":"6","key":"10.1016\/bs.irn.2018.08.007_bb0855","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1046\/j.1471-4159.2002.01084.x","article-title":"Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease","volume":"82","author":"Yohrling","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"3","key":"10.1016\/bs.irn.2018.08.007_bb0860","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ana.410200305","article-title":"PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline","volume":"20","author":"Young","year":"1986","journal-title":"Annals of Neurology"}],"container-title":["International Review of Neurobiology","Imaging in Movement Disorders: Imaging in Atypical Parkinsonism and Familial Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774218300746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T17:25:56Z","timestamp":1751822756000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774218300746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128151419"],"references-count":173,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2018.08.007","relation":{},"ISSN":["0074-7742"],"issn-type":[{"type":"print","value":"0074-7742"}],"subject":[],"published":{"date-parts":[[2018]]}}}